Guardant Health, Inc. (NASDAQ:GH) Director Stanley J. Meresman sold 4,934 shares of the business’s stock in a transaction dated Friday, September 10th. The stock was sold at an average price of $129.78, for a total value of $640,334.52. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Stanley J. Meresman also recently made the following trade(s):
- On Tuesday, August 10th, Stanley J. Meresman sold 4,934 shares of Guardant Health stock. The stock was sold at an average price of $114.31, for a total value of $564,005.54.
Guardant Health stock opened at $127.01 on Wednesday. The stock has a market capitalization of $12.87 billion, a price-to-earnings ratio of -33.69 and a beta of 0.51. Guardant Health, Inc. has a 52-week low of $96.66 and a 52-week high of $181.07. The stock’s 50 day moving average price is $116.63 and its two-hundred day moving average price is $129.23. The company has a debt-to-equity ratio of 1.44, a quick ratio of 19.30 and a current ratio of 19.57.
Several institutional investors have recently bought and sold shares of the business. Sandy Spring Bank lifted its holdings in shares of Guardant Health by 3,333.3% in the 2nd quarter. Sandy Spring Bank now owns 206 shares of the company’s stock worth $26,000 after purchasing an additional 200 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Guardant Health by 895.7% in the 1st quarter. Meeder Asset Management Inc. now owns 229 shares of the company’s stock worth $38,000 after purchasing an additional 206 shares in the last quarter. Tsfg LLC lifted its holdings in shares of Guardant Health by 214.0% in the 2nd quarter. Tsfg LLC now owns 314 shares of the company’s stock worth $39,000 after purchasing an additional 214 shares in the last quarter. Altshuler Shaham Ltd bought a new position in shares of Guardant Health in the 1st quarter worth $44,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Guardant Health in the 2nd quarter worth $50,000. Hedge funds and other institutional investors own 87.58% of the company’s stock.
Several research analysts have recently issued reports on the company. William Blair reaffirmed a “buy” rating on shares of Guardant Health in a research note on Thursday, May 27th. Zacks Investment Research raised Guardant Health from a “sell” rating to a “hold” rating in a research note on Monday, August 16th. Canaccord Genuity lowered their price objective on Guardant Health from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, August 9th. The Goldman Sachs Group assumed coverage on Guardant Health in a research note on Thursday, June 3rd. They issued a “buy” rating and a $160.00 price objective for the company. Finally, SVB Leerink reaffirmed a “buy” rating on shares of Guardant Health in a research note on Sunday, May 23rd. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Guardant Health currently has an average rating of “Buy” and a consensus price target of $164.00.
About Guardant Health
Guardant Health, Inc is a precision oncology company, which engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H.
Further Reading: How does a reverse stock split work?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.